Loading clinical trials...

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies

NCT01163552•St. Luke's-Roosevelt Hospital Center

View on ClinicalTrials.gov

Summary

Cancers that have spread to the inner lining of the chest are classified as Stage IV and bear a poor prognosis. Surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options. This study intends to evaluate whether surgical removal of all visible tumor on the chest wall followed by bathing the chest cavity in heated chemotherapy solution will improve outcomes for these advanced cancers.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adults aged 18-75 years
•2. Radiographic evidence of pleural dissemination with histologically or cytologically confirmed diagnosis.
•3. Primary source control (breast, ovarian, uterine, colon, renal cell, thymic cancer)
•4. Adequate liver and renal function defined as a bilirubin of \< 2.0 mg/dl, albumin \> 3.0g/dl, and a creatinine of \< 1.5 mg/dl, respectively.
•5. Absolute neutrophil count (ANC) of ≥1,500/mm3 and a platelet count ≥100,000/mm3.
•6. A Karnofsky Performance Status score of ≥60

Exclusion Criteria

•1. Patients without satisfactory oncological control of their primary cancer.
•2. Radiographic evidence of abdominal, pelvic, or intracranial metastatic disease.
•3. Chemotherapy and/or radiotherapy must have been completed at least one month prior to entry in the study. Patients may not receive concurrent chemotherapy, immunotherapy, radiotherapy, or any investigational drugs while participating in this study.
•4. Significant active medical disease including, but not limited to:
•* Cardiac disease, including: congestive heart failure or angina pectoris; recent (within 1 year) history of a myocardial infarction; uncontrolled hypertension; arrhythmias.
•* Active infections
•* Uncontrolled diabetes mellitus
•* Chronic renal insufficiency
•* HIV/AIDS - routine HIV testing will not be performed, but patients known to be HIV positive will be excluded.
•5. Pregnant or lactating women.
+1 more criteria

Locations (1)

St. Luke's-Roosevelt Hospital Center

New York, New York, United States

Key Dates

Start Date

June 1, 2010

Primary Completion Date

May 1, 2014

Completion Date

May 1, 2014

Last Updated

June 13, 2014

Enrollment

ACTUAL participants

Conditions

Pleural MetastasesBreast CancerColon CancerOvarian CancerUterine CancerRenal Cell CancerThymic Cancer

Interventions

Surgical debulking and Intrathoracic Hyperthermic Chemotherapy

PROCEDURE

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

Inclusion Criteria

Exclusion Criteria

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer